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Abstract 
Thyroid disorders are common endocrine disorders in the United States, affecting 
women more often than men. Due to the higher incidence of thyroid dysfunction in 
women, recent studies have been conducted to determine whether hypothyroidism could 
play a role in pregnancy complications. While studies have shown that clinical 
hypothyroidism can pose a threat to both the mother and child, fewer studies have 
investigated subclinical hypothyroidism. Therefore the aim of this systematic review was 
to determine the associations between subclinical hypothyroidism, in relation to increased 
thyroid stimulating hormone levels and normal tetraiodothyronine levels in pregnancy 
complications. The complications that were analyzed included placental abruption, 
premature delivery, low birth weight, intrauterine growth restriction, fetal and neonatal 
demise, and fetal distress. Odds ratios and relative risk ratios were collected from 11 
independent studies and analyzed using a meta-analysis. A summary estimate was 
calculated for each complication and the results were plotted on forest plots. Of the six 
complications measured, intrauterine growth restriction, placental abruption, fetal distress 
and fetal/neonatal demise were found to be associated with subclinical hypothyroidism. 
Further research is suggested in order to determine: 1) whether other pregnancy 
complications, in addition to those researched in this study, may be related to subclinical 
hypothyroidism, and 2) how subclinical hypothyroidism compares to overt (clinical) 
hypothyroidism in terms of these pregnancy complications. 
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Introduction 
 
The thyroid gland is a small yet vital organ within the endocrine system. The 
thyroid is responsible for synthesizing and releasing hormones that regulate essential 
functions such as growth, metabolism, and temperature. The process of thyroid hormone 
production involves the hypothalamus, the pituitary gland, and the thyroid gland, which 
work in a feedback mechanism known as the hypothalamic-pituitary-thyroid (HPT) axis. 
The HPT axis begins in the hypothalamus of the brain where neuronal cell bodies in the 
paraventricular nucleus synthesize thyrotropin-releasing hormone (TRH). TRH is passed 
through the hypothalamic pituitary-portal system to the anterior pituitary to stimulate the 
synthesis and release of thyroid stimulating hormone (TSH) by thyrotrophs within the 
pars distalis. TSH is then released from the anterior pituitary where it acts on follicular 
cell receptors on the thyroid gland to stimulate the synthesis and production of 
triiodothyronine (T3) and tetraiodothyronine (T4) hormones45. Due to its longer half-life, 
the majority of thyroid hormones traveling in the blood are T4. To exert its effects when 
leaving the blood, T4 is then converted to T3 by the removal of an iodine atom4. When 
T3 and T4 reach a higher than normal concentration in the body, these hormones will act 
in a negative feedback manner. The negative feedback loop works by T3 and T4 
signaling the hypothalamus and pituitary gland to stop the release of TRH and TSH, thus 
inhibiting further production of thyroid hormones in order to establish homeostasis45.  
Thyroid complications are one of the most common endocrine disorders within 
the population. Approximately 20 million people living in the United States have some 
form of thyroid disorder-12 million of which are undiagnosed40. Remarkably, the 
majority of these affected individuals are women as opposed to men. Women are 5 to 8 
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Figure 1. Hypothalamic-Pituitary-Thyroid axis of patients that are euthyroid (left), or have 
subclinical hypothyroidism (center) or overt hypothyroidism (right).  
times more likely to developed a thyroid disorder then men. Moreover, 1 in every 8 
women will eventually be diagnosed with a thyroid disorder in her lifetime40. 
Of the different types of thyroid disorders, hypothyroidism is the most common in 
women. Subclinical hypothyroidism (SCH) is defined as a high TSH concentration with a 
normal range of serum T4. Overt hypothyroidism (OH) is defined as a high TSH 
concentration with low serum T4 concentrations (Figure 1). The prevalence of SCH is 
higher than OH, affecting 4 to 8% of the US adult population38.  
 
 
 
 
 
 
 
 
 
 
  
 
Symptoms of hypothyroidism include fatigue, weight gain, decreased heart rate, 
dry hair and skin, sensitivity to cold, and potential swelling of the thyroid gland 
(goiter)43. If untreated, hypothyroidism can lead to cardiac dysfunction, neuropsychiatric 
symptoms and increase in low-density lipoprotein (LDL) cholesterol38. Because 
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hypothyroidism is relatively common and undiagnosed in women, there is increased 
concern that these thyroid disorders may consequently affect pregnancies.   
During pregnancy, the fetus relies heavily on its mother to synthesize essential 
hormones. As a result, hormone levels in the mother fluctuate greatly. For instance, the 
maternal thyroid gland must produce twice as much thyroid hormone during pregnancy in 
order to supply enough thyroid hormones for both the mother as well as the developing 
fetus24. However, if a pregnant woman has an undiagnosed thyroid disorder, she may not 
be able to provide an adequate amount of hormones, which is essential for both her and 
her fetus. Ultimately, an insufficient amount of thyroid hormones may lead to severe 
pregnancy complications18. Many studies have demonstrated the detrimental affects of 
OH and decreased levels of T3 and T4 on pregnancy1, 2, 29. 
Even though the maternal thyroid is crucial for a fetus, universal screening for 
thyroid disorders has yet to be established11. The American College of Obstetricians and 
Gynecologists and the clinical practice guidelines of the Endocrine Society recommend 
to only screen for women who are presenting symptoms or have a history of thyroid 
diseases13. Though it is well understood that OH can cause pregnancy complications, 
there is not a high enough prevalence of OH in the United States to justify screening. 
Women diagnosed with OH are often times infertile and unable to conceive which 
decreases the prevalence of pregnant women with OH even further37. In SCH, these 
women are able to maintain a normal range of thyroid hormones, and are thus not 
believed to be at risk for pregnancy complications. Thus universal screening for SCH has 
also yet to be established.  
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While several studies have demonstrated the risk of OH in women who are able to 
conceive1, 2, 29, fewer studies have been carried out regarding SCH. Due to a higher 
incidence of women with SCH versus OH, the aim of this systemic review was to 
determine whether an increased maternal TSH level and normal serum T4 levels, as seen 
in SCH, could also be associated with pregnancy complications. In this study, a meta-
analysis was performed on 11 different studies to generate an overall effect size for each 
complication. Results were then used to make a recommendation for universal thyroid 
screening in pregnancies.   
 
Methods 
Inclusion Criteria 
 Research for potential studies used in this systematic review and meta-analysis 
began on February 1, 2015 and ended on September 1, 2015. Keywords, “subclinical 
hypothyroidism” and “pregnancy” were used to find studies in the PubMed and Google 
Scholar databases. Search criteria included: 1) total sample size of at least 300 people; 2) 
results included at least one of following complications- placental abruption, premature 
delivery, low birth weight, intrauterine growth restriction, fetal distress, and/or fetal and 
neonatal demise; 3) studies were reported in English; 4) Levothyroxine treatment was not 
administered; 5) SCH was defined as an increased TSH level with a normal concentration 
of FT4. Any study that defined SCH as high TSH without measuring FT4 was excluded, 
as well as studies that failed to meet any other criteria. Figure 3 below describes the 
methods used in order to find eligible studies that met these criteria.  
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Assessment of Pregnancy Complications  
Placental abruption is the premature separation from uterine lining of a normally 
implanted placenta prior to delivery5, 13, 14. Previous research has demonstrated that 
placental abruption can lead to additional pregnancy risks such as premature birth, low 
birth weight, intrauterine restriction and stillbirth5.  
Premature delivery is defined as birth before 34-37 weeks of gestation and very 
premature birth is defined as birth before 34 weeks of gestation9, 12-14, 19, 20, 25, 29, 20, 37. In 
the present study, premature and very premature birth where classified together as one 
complication and defined as premature if birth occurred before 37 weeks. Prematurity is a 
18,000 results for “Subclinical 
Hypothyroidism Complicating 
Pregnancy” Google Scholar/PubMed 
3,890 results included at least 1 
pregnancy complication  
2,012 results yielded both control 
and SCH populations  
1,700 were excluded 
312 were reviewed for additional 
inclusion criteria 
 
11 relevant studies were eligible in 
this review 
Figure 2.Flow chart describing the method for incorporating relevant 
studies for this review 
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significant risk as it can cause chronic lung disease, developmental delay, growth 
reduction, hearing impairment, neonatal infections, respiratory distress syndrome, 
intraventricular hemorrhage and more42.  
Low birth weight is classified as neonatal weight less than 2500 gm after birth2, 12-
14, 20, 37. This complication can lead to an increased threat of infant mortality and 
childhood morbidity22. 
Intrauterine growth restriction is a decreased in growth rate of a fetus during 
gestation. Intrauterine growth restriction occurs when a fetus’ developmental rate is less 
than 10th percentile of its gestational age2, 9, 12, 13, 29. This complication poses a significant 
threat as it can lead to fetal hypoxia and perinatal mortality21.  
Of the studies included, only one gave a description of fetal distress. In this study, 
fetal distress was defined as fetal heart rate less than 120 beats per minute or greater than 
160 bpm, presence of meconium (fetal feces), signs of abnormal fetal movement, and 
fetal scalp pH less than 7.2213. In another study entitled What is Fetal Distress26, the 
authors claim that fetal distress is due to the onset of asphyxia where the fetus is deprived 
of oxygen due to insufficient uterine or umbilical blood flow. This stress can lead to 
irregular fetal heart rate patterns such as late decelerations, variable decelerations, or 
prolonged bradycardia26 (slow heart rate). Fetal distress can cause neonatal 
encephalopathy, where the brain’s function or structure is impaired, as well as impaired 
development of the central nervous system2, 32, 37. 
For the purpose of this present study, fetal and neonatal demise were defined as a 
terminated pregnancy at any duration during gestation. Death during the first 28 days of 
life was also included in order to account for neonatal demise. There are several ways of 
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classifying terminated pregnancy including fetal demise, miscarriage, spontaneous 
abortion, stillbirth, and neonatal demise. These terms were thus classified together as one 
complication.   
 
Defining Subclinical Hypothyroidism 
The diagnosis of SCH varied within the several studies included in this project. 
For this reason, guidelines according to the American Thyroid Association were used to 
establish a single reference range. The American Thyroid Association recommends the 
specific reference range for TSH levels during each trimester should be 0.1–2.5 mIU/L in 
the first trimester, 0.2–3.0 mIU/L in the second trimester, and 0.3–3.0 mIU/L in the third 
trimester35. The first trimester is marked by a decreased level of TSH due to the increase 
in human chorionic gonadotropin (hCG) secretion from the placenta, which binds to TSH 
receptors in the brain. As hCG levels decrease throughout the pregnancy, TSH 
increases35.  
When diagnosing SCH, free tetraiodothyronine (FT4) are measured instead of T4. 
T4 hormones are bound to albumin and thyroid binding globulin (TBG) in the blood, 
which prevents them from entering target tissues. FT4, however, is free to enter and exert 
its effects4. When measuring FT4 during the duration of a pregnancy, FT4 appears to 
have an inverse affect with TSH. Trimester specific levels of FT4 are as follows: 
1.13±0.23 ng/dLin the first trimester, 0.92±0.30 ng/dL in the second trimester, and 
0.86±0.21 ng/dL in the third trimester35. 
Overall, the American Thyroid Association states that SCH during pregnancy 
may be defined as a serum TSH between 2.5 and 10 mIU/L with a normal FT4 
concentration35. The average interval of FT4 in each trimester is between 0.6 and 1.3 
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ng/dl. Because the studies used in this current project ranged in the time of SCH 
screening from 13 to 40 weeks, this range of FT4 was used to define this disease in all 
three trimesters.  
 
Data Analysis  
Listed in Table 1 and 2 of the appendix are the 11 studies that were included in 
this project. The combined number of women with SCH from each number was 2,272. 
Nationality ranged worldwide across eight different countries. Age of participants among 
total population sizes also varied between 20 to 40 years of age. Each study was carried 
out as a prospective cohort in which subclinical hypothyroid and euthyroid (control) 
participants were followed throughout their pregnancies. In these prospective cohorts, a 
correlation between euthyroid (control) and hypothyroid (tested) populations were 
determined and effects sizes were reported.  
Effect sizes are reported as either an odds ratio (OR) or risk ratio (RR), which 
allows the comparison between an exposure and outcome. An OR determines the odds 
that an outcome will occur for a given exposure as compared to the odds of the outcome 
occurring in the absence of that exposure. Relative risk is the probability of an event 
occurring in an exposed population as compared to the probability of the same event 
occurring in a non-exposed group. Because some studies in this project reported OR 
while others gave RR, both effect sizes were used.  
If the effect sizes were not reported, which was true for four studies 2, 14, 20, 15, the 
effect sizes were calculated from the raw data using a 2x2 contingency table46 (Figure 3). 
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In three studies12, 13, 19 , effect sizes were reported for only certain complications. For the 
complications that were not reported, these effect sizes were also calculated by raw data. 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
   Odds Ratio = AD/BC 
 
  Figure 3. 2x2 Contingency Table for calculation of odds ratio and risk ratio.  
 
From the effect sizes, confidence intervals were generated and used to calculate 
the standard errors for each pregnancy complication. Confidence intervals measure the 
precision of the effect size within that study. Smaller confidence intervals are more 
precise and typically indicate the result of a larger sample size. Thus, smaller confidence 
intervals are assigned a higher weight in the meta-analysis.    
The effect sizes and standard errors were used to run a meta-analysis and the 
results where plotted on a forest plot for each complication. A summary effect was 
generated using R software (version 3.2.2) and meta-package, which reported the 
weighted mean of the individual effects.  
The two types of summary effects reported in a meta-analysis are the fixed effect 
model and the random effect model. The fixed effect model is used in cases where every 
study included in the meta-analysis is functionally equivalent. The goal is to then 
                          
A / n1 
C / n2 
Risk Ratio= 
 13 
generate a summary effect for an identical population. This model assumes common 
effect sizes between studies and variation is thus only accounted for within studies. The 
random effect model is used when generalizing results from studies that have been 
conducted by independent researchers with different population sizes. Random effect 
takes into account the variation within each study plus the variation between studies.  
In this meta-analysis, results from 11 independent studies where included and 
therefore the random effect model was used to generate a forest plot. The p-value of 
between study significance as well as the test for heterogeneity were also reported. A p-
value of less than 0.05 was used to indicate significant difference between studies. 
Heterogeneity refers to variation between studies, which was reported as I2. A higher I2 
percentage was reflective of higher heterogeneity between studies.   
 
Results 
 
 The summary effects from each study were computed for six pregnancy 
complications and the data were organized onto separate forest plots. The vertical line 
through the value of 1 indicates the reference line, or the line of no effect. An effect size 
equal to 1 implies that there is no relation or difference in risk between SCH and the 
pregnancy complication. An effect size greater than 1 implies that that SCH is positively 
related, or more likely to occur, in that pregnancy complication. If the effect size value is 
less than 1, then SCH is negatively related, or less likely to occur for that pregnancy 
complication. The size of the boxes indicates the weight, which is calculated by taking 
the inverse of the variance for that particular study. Therefore the study with the lowest 
variation, which is also commonly due to a larger population size, is assigned the highest 
weight. A large population size is also indicative of a smaller confidence interval, which 
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again reflects a smaller variance and is represented by a horizontal line through the effect 
size. At the end of the forest plot, depicted in red, is the summary effect. Both fixed and 
random effects are reported, however, only the random effects are displayed on the forest 
plots. As mentioned previously, a random effect size is more appropriate to use for this 
meta-analysis due to the fact that independent researchers with different population sizes 
conducted each study. The red dotted line runs through the summary effect value in order 
to better interpret the trend between studies.  
Of the six complications measured, four were positively related with SCH: fetal 
distress, intrauterine growth restriction, placental abruption, and fetal/neonatal demise.  
Low birth weight had a random effect size of 1.16 (fixed effect = 1.21) and a non-
significant p value of 0.57. This random effect size is only slightly above 1 and therefore 
was not regarded as a statistically significant, positive relation. The random effect size for 
premature delivery was 0.98 (fixed effect = 0.79) with an insignificant p value of 0.97. 
The random summary effect for premature birth was almost exactly the null value 
indicating that the SCH group and the euthyroid group were at the same odds or risk of 
having a preterm birth.   
Five studies were included in the analysis of fetal distress (Figure 4). After 
weighing the individual effect sizes for fetal distress, the random effect summary was 
1.84, which implies that women with SCH were 1.84 times more likely to develop fetal 
distress then the control group (fixed effect = 1.64). The confidence interval was 1.14-
2.97 meaning that there is 95% confidence that the true random effect summary fell 
within this range. Due to the fact that the confidence interval did not include the null 
value of 1, the p value was significant (p value = 0.012). The heterogeneity p value 
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(0.016) was also significant indicating that at least one study was significantly different 
from the rest, which furthers the reason to use a random effect summary value as 
compared to the fixed effect. This point is also illustrated by an I2 percentage of 66.9% 
heterogeneity.  
As depicted on the forest plot in figure 4, it can be inferred that Chen, et al., and 
Casey, et al., had much smaller confidence intervals as opposed to the other studies. This 
difference may be explained by their sample sizes that were several thousand times 
larger. Chen, et al., and Casey, et al., also adjusted for several variables whereas the 
remaining studies did not report any adjustment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Individual effect sizes and summary estimates of the association between SCH and fetal distress 
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For intrauterine growth restriction (Figure 5), the random effect summary was 
2.023 (fixed effect = 2.13) therefore making the SCH group over two times more likely 
of developing IUGR. Due to the fact that the confidence interval did not include the value 
of 1, the p value was again significant (0.013). Though the effect size was large, 
indicating a positive relation, only four studies measured intrauterine growth restriction. 
However, three of the four included studies reported an effect size greater than 1 
indicating a positive relation between SCH and intrauterine growth restriction. As seen in 
red in the forest plot in figure 5, the test for heterogeneity p value was not significant. 
However, the I2 value still reflected heterogeneity between the included studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Individual effect sizes and summary estimates of the association between SCH and intrauterine 
growth restriction 
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The random effect summary for placental abruption was 2.072 (fixed effect = 
2.071) with a significant p value of 0.038. Again, this pregnancy complication was 
almost two times more likely for the SCH group as compared to the euthyroid group 
(Figure 6). Even though only four studies included this complication as well, three were 
in agreement with an association between SCH and placental abruption. The 
heterogeneity p value was 0.23, which doesn’t meet the cut off for significance, however, 
the I2 percentage of 30.1% reflects some variation between these studies. Cleary-
Goldman, et al., was a slight outlier in this meta-analysis, however this may be explained 
by the fact that they adjusted for previous birth complications that decreased a large 
amount of variation within their study.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Individual effect sizes and summary estimates of the association between SCH and placental 
abruption 
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Finally, fetal and neonatal demise had a random effect summary of 1.81 and a 
significant p value of 0.001 (Figure 7). The fixed affect value was identical in this meta-
analysis (1.81) and the I2 was 0%. Though these studies were not identical, as they had 
different population sizes, a 0% heterogeneity could be explained by the fact that they 
each had the same standard error and therefore were very similar. All eight individual 
studies reported effect values above the null value for fetal and neonatal demise, which 
suggests a strong relation between SCH and fetal and neonatal demise. An outlier in this 
meta-analysis was in the Negro, et al., however, this study did not report their covariates 
and it is unclear as to why their confidence interval is much smaller in comparison to the 
other studies.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Individual effect sizes and summary estimates of the association between SCH and fetal and 
neonatal demise 
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Discussion 
Physiological Rational  
The present meta-analysis, indicates that SCH may be positively related to 
pregnancy complications. Four of the pregnancy complications were significantly 
associated with SCH, and every pregnancy complication was more closely associated 
with SCH verses euthyroid groups. The physiological reason behind why an elevated 
level of TSH and normal levels of T3 and T4 are associated with these complications is 
not well understood. However, below are three plausible explanations for these results.  
Several studies have demonstrated that an increase in TSH concentration can 
cause high blood pressure7, 15, 44. Hypertension in pregnant women can pose a threat to 
her developing child as it may lead to decreased blood flow and oxygen to the placenta. 
In several studies3, 5, 10 , complications, such as fetal demise, placental abruption, and 
others have been shown to be the result of maternal high blood pressure. Therefore, there 
may be a cascade of events in which SCH induces high blood pressure in women who are 
then at a higher risk of several different complications during pregnancy.  
Another explanation is derived from the negative feedback loop of the HPT axis. 
As mentioned previously, T3 and T4 work to shut off the production of TRH and TSH in 
the brain. However, if thyroid hormones are not working properly, these hormones can 
cause an increase in production of TRH, which acts tropically on TSH to increase its 
production. TRH not only works to increase the production of TSH, however, it also 
increases levels of prolactin released from the pituitary gland, which can lead to 
hyperprolactinemia, or the overproduction of prolactin. 
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Hyperprolactinemia is often seen in patients diagnosed with SCH27. High TRH 
levels, resulting in an increase in prolactin concentrations, have also been shown to be 
associated with miscarriages17, 23. Elevated levels of prolactin can lead to a decrease in 
progesterone, which is crucial to maintain a pregnancy. Without progesterone, the corpus 
luteum is unable to survive, which then results in a miscarriage8. Therefore, women with 
elevated levels of TSH and prolactin are at a higher risk of having a prematurely 
terminated pregnancy than those who are not.  
A final explanation as to why SCH can cause pregnancy complications may be 
due to the consequences of an underlying autoimmune disease. Hypothyroidism is often 
the result of an autoimmune disorder known as Hashimoto’s disease. In the latter disease, 
antibodies such as thyroid peroxidase antibodies (anti-TPO) destroy the enzymes 
responsible for synthesizing thyroid hormones. Although it is unclear whether these 
antibodies can cross the placenta and cause complications, certain studies34, 39 have 
suggested that these auto reactive antibodies can be harmful to a developing fetus. 
Limitations 
 Throughout the course of the present meta-analysis, certain limitations impacted 
the results. For instance, within each study there was a difference in the reported 
conditions such as the diagnostic criteria of SCH, the timing of SCH screening as well as 
their adjusted variables. In the studies investigated, normal TSH levels ranged between > 
2.5-5.5 mIU/L. This range is potentially problematic, as studies focusing on the higher 
end of TSH concentrations may have missed complications in women they defined as 
euthyroid. Timing of screening may have also impacted the results. Screening for SCH 
ranged throughout the entire gestational period. Some studies that diagnosed SCH during 
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the first trimester, did not focus on women who may have developed the disorder later in 
their pregnancy. The present meta-analysis, therefore, did not adjust for timing of 
diagnosis. The adjusted variables ranged from delivery gestation age, maternal age, body 
mass index, exposure to smoking, parity, ethnicity, maternal height, and neonatal sex. 
However, consistency was not met between studies. Another variation was the range in 
ethnicity. Ethnic discrepancies were not taken in account when generating the results, 
which may have also had an impact. Since only two studies used in this meta-analysis 
were conducted in the United States, it is difficult to advocate for or against universal 
screening in North America. A final limitation was the size of available studies used in 
the meta-analysis. Due to the fact that SCH complicating pregnancies is a relatively new 
concept, little research has thus far been conducted on this matter. 
 
Recommendations for Future Research 
 Debate regarding whether to screen for thyroid diseases is ongoing, as experts 
involved in producing guidelines on thyroid diseases during pregnancy have not reached 
a consensus. Those in favor of screening claim that, due to the inexpensive cost of 
screening and treating thyroid diseases, many women may be spared from experiencing 
pregnancy complications24. Those against screening do not believe these disorders meet 
the criteria for universal screening. According to the US Preventative Services Task 
Force, criteria used to initiate new population screening includes: 1) the diagnosis of the 
disease should be prevalent or important enough to justify screening; 2) clear evidence of 
negative outcomes associated with the diagnosis; 3) an intervention that should 
improvement in the outcome; and 4) screening should be cost effective11. Though OH has 
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been shown to cause complications during pregnancy, the prevalence of OH is only 
0.02%. For this reason, the current stance on the matter is not to include women with 
SCH, for lack of a high enough prevalence of this disease to implement universal 
screening11. 
  According to the results of this meta-analysis, there may be reasons to believe 
that high TSH and normal T4 concentrations in the blood, as seen in patients with SCH, 
can result in pregnancy complications. For this reason, the prevalence of SCH should be 
included in the case for universal screening as it occurs in 4-8% of the US adult 
population38. Additional research needs to be done to determine the associations of SCH 
and pregnancies specifically in the United States population. Preceding these studies, 
additional research should be conducted to determine whether treatment of thyroid 
diseases alleviates this issue. If future research also demonstrated a correlation between 
SCH and pregnancy complications, and viable treatment options are available, then the 
four recommended criteria would be met for implementations of universal screening for 
thyroid disorders. 
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Appendix  
 
 
 
 
 
 
 
 
 
Study Country Mean Age 
± SD 
Time of 
Screening 
(weeks) 
Measured Birth Defects 
Casey, et al., 2005 United States 26.9 ± 5.9 
 
< 20  Preterm delivery, very preterm delivery, 
placental abruption, neonatal/fetal demise, 
fetal distress, LBW 
Saki, et al. 2014 Iran 25.8 ± 3.5 
 
15-28 IUGR, preterm delivery 
Sahu, et al. 2010 India 27.2 ± 4.1 
 
13-26 Fetal distress, premature delivery, IUGR, 
fetal/neonatal demise 
 
Su, et al., 2011 China 20-42 
 
20 Spontaneous abortion, fetal death, neonatal 
death, fetal distress, preterm delivery, LBW 
 
Ajmani, et al. 2014 India 24.51 ± 4.71 
 
13-26 LBW, preterm delivery 
 
Breathnach, et al., 
2013 
Australia/New 
Zealand 
27 ± 5 
 
13-27 Premature delivery, IUGR, placental 
abruption  
 
Korevaar, et al, 
2013 
Netherlands 29.7 ± 5 
 
13.2 Premature delivery  
 
Negro, et al., 2010 Italy  28.7 ± 5 
 
1-12 Fetal/neonatal demise, premature delivery  
Cleary-Goldman, et 
al., 2008 
United States 29.8 ± 5.7 
 
1-27 Fetal/neonatal demise, placental abruption, 
LBW  
 
Mannisto, et al., 
2009 
Finland 28.6 ± 5.8 
 
1-12 LBW, premature delivery, fetal/neonatal 
demise 
 
Chen, et al., 2014 China 26.33 ± 0.24 
 
1-40 LBW, fetal/neonatal demise, premature 
delivery, placental abruption, fetal distress, 
IUGR 
 
Table 1. Demographics and measured birth defects between 11 studies included in the meta-
analysis  
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Study Euthyroid 
Sample 
Size 
SCH 
Sample 
Size  
Effect Size  SCH Criteria  Covariates 
Casey, et al., 
2005 
15689 
 
404 RR Elevated TSH levels (2.74-
5.09 mU/L). Normal free 
thyroxine (>0.680ng/dL) 
 
Maternal age, race, 
and placental 
abruption 
 
Saki, et al. 2014 497 
 
66 RR Elevated TSH levels (3-
10mIU/L) Normal free 
thyroxine 
 
Delivery gestation 
age, maternal body 
mass index, age of 
mother, and 
occurrence 
of preeclampsia. 
 
Sahu, et al. 
2010 
552 
 
41 RR Elevated TSH >5.5 mIU/L. 
Normal T4 
 
Not reported 
Su, et al., 2011 845 
 
41 OR TSH greater 
than the 95th percentile and 
a fT4 between the fifth and 
95th 
percentiles 
 
Maternal age, parity, 
and BMI. 
 
Ajmani, et al. 
2014 
347 
 
36 RR 
(calculated) 
TSH>3.0 lIU/l with normal 
levels of FT4 (0.8–2.0 
ng/dl).  
 
Not reported 
Breathnach, et 
al., 2013 
870 
 
16 RR 
(calculated) 
TSH values at or above the 
98th percentile (>4.1 mU/L) 
with a normal free 
thyroxine above 2nd 
percentile 
 
Not reported 
Korevaar, et al, 
2013 
4970 
 
188 OR TSH >4.04 mU/L and 
normal FT4 (2.5th–97.5th 
percentiles) 
 
maternal smoking 
status,BMI, 
gestational age at 
blood sampling, 
maternal age, 
smoking, SES, parity, 
ethnicity, maternal 
BMI, maternal 
height, and child sex 
 
Negro, et al., 
2010 
3481 
 
642 RR 
(calculated) 
TSH between 2.5-5.0 mIU/L 
Normal T4 levels 
 
Not reported 
Table 2. Characteristics of studies assessing SCH and pregnancy complications  
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Cleary-
Goldman, et al., 
2008 
10021 
 
243 RR 
(calculated) 
TSH levels above the 97.5th 
percentile and FT4 
between the 2.5th and 
97.5th percentiles 
 
Age, prior 
pregnancy, body 
mass index, and 
study site. 
 
Mannisto, et al., 
2009 
4719 
 
224 RR 
(calculated) 
TSH (mU/liter) > 3.6 and 
TT4 (pmol/liter) 11.96-20.5 
 
Maternal age and 
parity. 
 
Chen, et al., 
2014 
7641  
 
371 OR TSH exceeding trimester 
specific range with normal 
FT4: first trimester, TSH 
0.09–3.47mIU/L and fT4 
6.00–12.25 ng/L; second 
trimester, TSH 0.20– 
3.81 mIU/L and fT4 4.30–
9.74 ng/L; and third 
trimester, TSH 
0.67–4.99 mIU/L and fT4 
4.56–8.50 ng/L. 
 
Maternal age, parity, 
gestational age at 
delivery, and 
exposure to 
husband's smoking  
 
